Pipeline
Umoja鈥檚 VivoVec-driven pipeline is driving numerous near-term catalysts
Program
Preclinical
PHASE 1鈥�
UB-VV400/410
NHL/Autoimmune
Preclinical
PHASE 1鈥�
Target
CD22
Milestone
Clinic 2025
In-Licensing Partner
IASO Biotherapeutics
NCT06743503
UB-VV300/310
NHL/Autoimmune
Preclinical
PHASE 1鈥�
Target
CD20
Milestone
IND enabling
UB-VV500
Multiple Myeloma
Preclinical
PHASE 1鈥�
Target
Undisclosed
Milestone
IND enabling
UB-VV111
Hematology
Preclinical
PHASE 1鈥�
Target
CD19
Milestone
Clinic 2025
Out-Licensing Partner
AbbVie
NCT06528301
Multiple
Hematology
Preclinical
PHASE 1鈥�
Target
Undisclosed
Milestone
Early development
Out-Licensing Partner
AbbVie
Multiple
Oncology
Preclinical
PHASE 1鈥�
Target
Undisclosed
Milestone
Early development
Out-Licensing Partner
AbbVie
Expanded Access & Compassionate Use Policy
听
国产传媒 is committed to developing innovative therapies through rigorous clinical research that address critical unmet needs. Currently, we do not offer access to our investigational therapies outside of clinical trials. We believe that participation in clinical trials is the most appropriate and equitable pathway for patients to access our investigational therapies until the safety and tolerability of each has been established and evaluated by regulatory authorities.
听
For more information about our ongoing studies, please visit . Search 鈥淯moja鈥� to find our clinical trials that may be recruiting. If you are a healthcare professional and would like more information on our investigational therapies, please send an inquiry to info@umoja-biopharma.com.
听
听
